Patients taking an obesity pill in clinical trials were more likely to report suicidal thoughts or actions, US drug reviewers have said. A Food and Drug Administration advisory panel will consider on Wednesday whether regulators should approve US sales.The FDA said the 20-milligram dose of the drug, Zimulti, produced clinically significant weight loss over one year.
